Clinical Study

REVOLUTIONARY PRODUCT for CHRONIC KIDNEY DISEASE

Format: PDF file | Document type: Clinical Study | Promoted Content

This Clinical Study has been written by THINQ Pharma-CRO Pte Ltd , and any views and opinions expressed do not necessarily reflect those of www.nutraingredients.com

REVOLUTIONARY PRODUCT for CHRONIC KIDNEY DISEASE

IS THERE AN ORALLY CONSUMABLE PRODUCT USEFUL FOR DECREASING SERUM CREATININE LEVEL, DECREASE IN BLOOD UREA NITROGEN, INCREASING eGLOMARULAR FILTRATION RATE AND IMPROVEMENT IN QUALITY OF LIFE IN CHRONIC KIDNEY DISEASE PATIENTS?

YES. The first orally consumable product for CHRONIC KIDNEY DISEASE is now patented in Europe (EP3247323) and is now available; 

FOR EXCLUSIVE SUB-LICENSING OF PATENT RIGHTS OR MARKETING RIGHTS  to LEADING SMALL/BIG HEATHCARE COMPANIES  for ENTIRE EUROPE or FOR INDIVIDUAL COUNTRIES IN EUROPE

Supplier info centre